Co-Diagnostics Q2 revenue falls to $0.2M from $2.7M; net loss $7.7M

Co-Diagnostics, Inc.

2025-Q2 EPS reported -$0.47 revenue$213,187

Revenue $0.2M vs $2.7M in Q2 2024; no grant revenue recognized in Q2 2025.
Operating loss $8.1M vs $7.7M prior year; expenses down 19.1% to $8.2M.
Net loss $7.7M ($0.23 per share) vs $7.6M ($0.25 per share) in Q2 2024.
Cash & marketable securities $13.4M as of June 30, 2025; adjusted EBITDA loss $7.2M.
On track to initiate clinical evaluations for Co-Dx PCR platform tests before year-end; enhanced COVID-19 test trial starting imminently.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.